Her research examines the power dynamic among the government, transnational medical companies, and individuals in the knowledge production of the HPV vaccination in mainland China. Since the HPV vaccine first appeared in the public in 2006, the advertising for HPV vaccination swept numerous countries, including China. However, the Chinese government did not approve the imported nonavalent HPV vaccine until WHO called for the elimination of cervical cancer caused by the HPV virus in 2018. I argue that a race for the HPV vaccines began in China in 2018 sponsored by the government. In response to the competition and short supply in the HPV vaccine market, the Chinese government also announced plenty of policies to accelerate the development of domestic vaccines, offer free domestic HPV vaccines for girls under fifteen, and strictly supervise the budget for imported HPV vaccines in hospitals. The state’s power highly controls individual perceptions of HPV vaccines and cervical cancer in the national HPV program, influenced by the global economy and gendered health. However, women did not passively accept the knowledge of HPV vaccines sponsored by the government and some of them shared their side effects online after getting domestic and imported HPV vaccinated. This paper also argues that their lived experiences constituted an important part of the HPV vaccination knowledge circulating in society.
